|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
107,850,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vaxcyte is a clinical-stage vaccine company. Co. is developing conjugate and protein vaccines to treat bacterial infectious diseases. Co.'s primary vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine (PCV) for the treatment of invasive pneumococcal disease and pneumonia. Co.'s second PCV candidate, VAX-XP, is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition, Co.'s pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep and VAX-PG, a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
132,527 |
297,711 |
366,947 |
577,759 |
Total Sell Value |
$9,422,498 |
$19,561,310 |
$23,008,468 |
$28,538,885 |
Total People Sold |
5 |
6 |
6 |
8 |
Total Sell Transactions |
17 |
37 |
45 |
83 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fairman Jeff |
VP, Research |
|
2021-12-20 |
4 |
OE |
$1.79 |
$8,000 |
D/D |
4,469 |
10,629 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-12-16 |
4 |
AS |
$22.50 |
$103,928 |
D/D |
(4,619) |
6,160 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-12-16 |
4 |
OE |
$1.79 |
$8,268 |
D/D |
4,619 |
10,779 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-12-09 |
4 |
AS |
$22.50 |
$2,948 |
D/D |
(131) |
6,160 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-12-09 |
4 |
OE |
$1.79 |
$234 |
D/D |
131 |
6,291 |
|
- |
|
Sauer Paul |
SVP Process Dev, Manufacturing |
|
2021-11-01 |
4 |
AS |
$25.00 |
$75,000 |
D/D |
(3,000) |
33,125 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-10-26 |
4 |
AS |
$22.69 |
$107,778 |
D/D |
(4,750) |
5,144 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-10-26 |
4 |
OE |
$1.79 |
$8,503 |
D/D |
4,750 |
9,894 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-10-20 |
4 |
AS |
$22.54 |
$338,756 |
D/D |
(15,000) |
580,254 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-10-20 |
4 |
OE |
$1.79 |
$26,850 |
D/D |
15,000 |
595,254 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-09-27 |
4 |
AS |
$26.16 |
$124,303 |
D/D |
(4,750) |
5,144 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-09-27 |
4 |
OE |
$1.79 |
$8,503 |
D/D |
4,750 |
9,894 |
|
- |
|
Sauer Paul |
SVP Process Dev, Manufacturing |
|
2021-09-22 |
4 |
AS |
$25.20 |
$133,724 |
D/D |
(5,307) |
36,125 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-09-22 |
4 |
AS |
$25.19 |
$105,636 |
D/D |
(4,193) |
580,254 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-09-22 |
4 |
OE |
$1.79 |
$7,505 |
D/D |
4,193 |
584,447 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-09-21 |
4 |
AS |
$25.17 |
$272,590 |
D/D |
(10,807) |
580,254 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-09-21 |
4 |
OE |
$1.79 |
$19,345 |
D/D |
10,807 |
591,061 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-08-26 |
4 |
AS |
$24.70 |
$120,543 |
D/D |
(4,750) |
5,144 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2021-08-26 |
4 |
OE |
$1.79 |
$8,503 |
D/D |
4,750 |
9,894 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-08-23 |
4 |
AS |
$22.73 |
$310,722 |
D/D |
(13,669) |
580,254 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-08-23 |
4 |
OE |
$1.79 |
$24,468 |
D/D |
13,669 |
593,923 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-08-19 |
4 |
AS |
$22.40 |
$29,810 |
D/D |
(1,331) |
580,254 |
|
- |
|
Pickering Grant |
Chief Executive Officer |
|
2021-08-19 |
4 |
OE |
$1.79 |
$2,382 |
D/D |
1,331 |
581,585 |
|
- |
|
Mitchell Jane Wright |
General Counsel |
|
2021-08-16 |
4 |
AS |
$26.00 |
$65,000 |
D/D |
(2,500) |
3,125 |
|
- |
|
Mitchell Jane Wright |
General Counsel |
|
2021-08-16 |
4 |
OE |
$2.03 |
$5,075 |
D/D |
2,500 |
5,625 |
|
- |
|
353 Records found
|
|
Page 10 of 15 |
|
|